Get the Stockscreener App
29.68
5.70%
1.60
After Hours:
30.27
0.59
+1.99%
Galecto Inc stock is traded at $29.68, with a volume of 203.96K.
It is up +5.70% in the last 24 hours and up +24.81% over the past month.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$28.08
Open:
$27.88
24h Volume:
203.96K
Relative Volume:
1.19
Market Cap:
$1.79B
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-20.47
EPS:
-1.45
Net Cash Flow:
$-36.91M
1W Performance:
-8.11%
1M Performance:
+24.81%
6M Performance:
+889.33%
1Y Performance:
+629.24%
1-Day Range:
$27.88
$30.34
1-Week Range:
$27.75
$32.62
52-Week Range:
$2.01
$38.33
Galecto Inc Stock (GLTO) Company Profile
Name
Galecto Inc
Sector
Industry
Phone
45-70-70-52-10
Address
75 STATE STREET, BOSTON
Compare GLTO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
29.68 | 1.69B | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | UBS | Buy |
| Jan-07-26 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Guggenheim | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
View All
Galecto Inc Stock (GLTO) Latest News
Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Galecto (GLTO) Issues Equity Awards to New Employees - GuruFocus
Galecto announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Biotech Galecto gives new hires options for 153,700 shares - Stock Titan
Galecto, Inc. (NASDAQ:GLTO) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Market Trends: Can Galecto Inc generate free cash flowEarnings Beat & Capital Protection Trading Alerts - baoquankhu1.vn
Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference - Bitget
Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 86.6% in February - Defense World
Market Moves: What are Galecto Incs growth leversWeekly Risk Report & Breakout Confirmation Trade Signals - baoquankhu1.vn
Update Report: Can Galecto Inc beat the S P 500Chart Signals & Growth Focused Stock Pick Reports - baoquankhu1.vn
Bull Bear: How sensitive is Galecto Inc to inflationShort Setup & AI Enhanced Trading Alerts - baoquankhu1.vn
GLTO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Stock Market Recap: Whats the profit margin of Galecto IncEarnings Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Will Galecto Inc. stock hit new highs in YEARPortfolio Return Report & Free Real-Time Market Sentiment Alerts - mfd.ru
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Galecto (GLTO) - The Globe and Mail
UBS initiates Galecto stock with buy rating on blood disorder drug - Investing.com Nigeria
GLTO: UBS Initiates Coverage with a 'Buy' Rating and $45 PT | GL - GuruFocus
UBS Initiates Coverage of Galecto (GLTO) with Buy Recommendation - Nasdaq
GLTO: Guggenheim Maintains Buy Rating and Raises Price Target to $40 | GLTO Stock News - GuruFocus
Galecto (GLTO) Is Up 21.3% After $316 Million Equity Raise and New $150 Million Shelf Registration - simplywall.st
Galecto (GLTO) Is Up 15.3% After $316 Million Equity Raise And New Shelf RegistrationWhat's Changed - Yahoo Finance
Galecto Closes $316 Million Public Offering of Common Stock - Global Legal Chronicle
Assessing Galecto (GLTO) Valuation After Sharp Short-Term Share Price Momentum - Yahoo Finance
Can Galecto Inc. lead its sector in growthJuly 2025 Gainers & Expert Verified Movement Alerts - mfd.ru
What is Galecto Inc.’s valuation compared to sector2025 Winners & Losers & Weekly Stock Performance Updates - mfd.ru
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million - The Manila Times
Why Galecto Inc. stock could be next big winnerDip Buying & AI Enhanced Market Trend Forecasts - mfd.ru
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million - Bitget
Galecto raises $316.3M as it develops blood cancer therapies - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Dividend Watch: Can Galecto Inc lead its sector in growthEarnings Miss & High Conviction Buy Zone Picks - baoquankhu1.vn
Galecto prices $275 million public offering at $19 per share By Investing.com - Investing.com Nigeria
Galecto Prices Upsized Public Offering to Fund DMR-001 - TipRanks
Galecto Signs Underwriting Agreement With Jefferies and Leerink Partners - TradingView
Galecto Prices Public Offering at $19.00 per Share, Expected to Raise $275M - Intellectia AI
Galecto shares fall after $275 million equity raise at discount - Investing.com
Galecto shares fall after $275 million equity raise at discount By Investing.com - Investing.com Canada
GLTO: Key Managers Involved in Recent Offering - GuruFocus
Galecto to raise USD 275m in share issue - medwatch.com
Galecto announces public offering of common stock and preferred shares By Investing.com - Investing.com Australia
Galecto Prices $275 Mln Public Offering At $19 Per Share, Stock Down - Nasdaq
Cancer drug developer Galecto raises $275M in stock sale - Stock Titan
Hans Schambye resigns from Galecto – takes top position at Boost Pharma - medwatch.com
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - 富途牛牛
Galecto Prices $275 Million Offering - marketscreener.com
Galecto stock falls after announcing public offering of common stock By Investing.com - Investing.com Canada
Galecto prices $275 million public offering at $19 per share - Investing.com India
Galecto Announces Pricing of $275 Million Underwritten Public Offering - The Manila Times
Galecto, Inc. Announces Pricing of $275 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Galecto announces pricing of $275 million underwritten public offering - marketscreener.com
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):